Skip to Primary Navigation

Skip to main content

FTC secures settlement in antitrust case targeting another ‘Big Three’ PBM   

A photo of the Federal Trade Commission's sign at front of its headquarters.
Photo: Kevin Carter/Getty Images

Kevin Kinsella

3 min read
 Click to share on Facebook (Opens in new window/tab) Click to share on Twitter (Opens in new window/tab) Click to share on LinkedIn (Opens in new window/tab) Click to share on WhatsApp (Opens in new window/tab)

The Federal Trade Commission says the settlement will increase transparency and competition across the entire drug supply chain.

The Federal Trade Commission (FTC) has reached a settlement with CVS Caremark, imposing new restrictions on the company’s business practices and advancing the agency’s broader effort to increase transparency and competition across the pharmacy benefit manager sector.

The consent agreement resolves an antitrust case focused on Caremark’s role

, , , , , , , ,

Get full access, free for a month

This is a Premium article. Start your 28-day free trial to continue reading and access all content on GRIP – no payment details required.

Start free trial Sign in

What’s included:

  • Every new article, plus our 5,000+ archive
  • Daily regulatory insight and guidance
  • Exclusive interviews and in-depth analysis
  • Coverage of industry-leading events and conferences
  • All podcasts and videos, featuring industry experts
  • The full set of Rules Navigator tools
  • An ad-free experience